ema glp-1 vision loss recommendation 2025 Drug Can Cause Rare, Potentially Blinding Side Effect, Warns ema glp-1 vision loss recommendation

Cell Biochem 114 , 844853 (2013)

This early conditioning can contribute to long-term unhealthy eating habits, increasing the risk of obesity and related metabolic dysfunction

Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain

Dai WL, et al

By doing so, they: Lower appetite and cravings Slow how quickly food leaves the stomach Improve insulin resistance

CagriSema FDA approval timeline Novo Nordisk submitted the New Drug Application (NDA) to the FDA on December 18, 2025 , for chronic weight management in adults with obesity or overweight with a weight-related comorbidity